Current and Future Perspectives in Thyroid Carcinoma Treatment.

Area of Science:

• Endocrinology
• Oncology
• Nuclear Medicine

Background:

• Thyroid nodules are common, requiring ultrasound and biopsy for evaluation.
• Differentiated thyroid carcinoma (DTC) is typically treated with surgery.
• Post-operative radioactive iodine (¹³¹I) ablation is standard for remnant thyroid tissue and recurrence detection.

Purpose of the Study:

• To review current and emerging treatments for thyroid cancer.
• To assess the efficacy of low-dose ¹³¹I ablation for low-risk DTC.
• To explore the role of multi-targeted kinase inhibitors in advanced DTC and anaplastic thyroid carcinoma.

Main Methods:

• Review of recent studies on ¹³¹I ablation protocols.
• Analysis of clinical data on multi-targeted kinase inhibitors (e.g., motesanib, sorafenib, lenvatinib) in advanced DTC.
• Discussion of treatment strategies for anaplastic thyroid carcinoma.

Main Results:

• Low-dose (30 mCi) ¹³¹I ablation with recombinant human thyrotropin may be adequate for low-risk DTC.
• Multi-kinase inhibitors targeting RET and VEGFR pathways are effective in metastatic DTC.
• Some agents (axitinib, pazopanib) primarily exhibit anti-angiogenic effects.
• Adjuvant chemoradiotherapy is an option for unresectable localized anaplastic thyroid carcinoma.

Conclusions:

• Optimized ¹³¹I ablation protocols can manage low-risk thyroid cancer effectively.
• Kinase inhibitors represent a significant advancement in treating advanced and metastatic differentiated thyroid cancers.
• Treatment approaches vary based on thyroid cancer subtype and stage, including surgery, ¹³¹I therapy, targeted therapies, and chemoradiotherapy.